Vistagen Therapeutics (VTGN) Sees Unusually-High Trading Volume

Shares of Vistagen Therapeutics Inc (NASDAQ:VTGN) saw an uptick in trading volume on Thursday . 1,047,700 shares changed hands during mid-day trading, an increase of 57% from the previous session’s volume of 667,381 shares.The stock last traded at $1.78 and had previously closed at $1.71.

Several brokerages have weighed in on VTGN. Oppenheimer set a $6.00 price objective on Vistagen Therapeutics and gave the company a “buy” rating in a research report on Sunday, November 4th. Maxim Group set a $6.00 price objective on Vistagen Therapeutics and gave the company a “buy” rating in a research report on Wednesday, October 3rd. ValuEngine upgraded Vistagen Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Finally, Zacks Investment Research upgraded Vistagen Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a research report on Thursday, August 30th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $8.30.

The firm has a market cap of $55.28 million, a P/E ratio of -1.62 and a beta of -1.53.

Vistagen Therapeutics (NASDAQ:VTGN) last announced its earnings results on Monday, October 29th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.13). Sell-side analysts predict that Vistagen Therapeutics Inc will post -1.1 earnings per share for the current year.

An institutional investor recently raised its position in Vistagen Therapeutics stock. Vanguard Group Inc. lifted its holdings in shares of Vistagen Therapeutics Inc (NASDAQ:VTGN) by 42.7% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 257,465 shares of the company’s stock after acquiring an additional 77,090 shares during the quarter. Vanguard Group Inc. owned approximately 0.83% of Vistagen Therapeutics worth $373,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 7.44% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at

Vistagen Therapeutics Company Profile (NASDAQ:VTGN)

VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.

Featured Article: Why Dividend Stocks May Be Right for You

Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit